Patrick Malone is a partner at KdT Ventures, an early-stage venture capital firm focused on the intersection of biology, chemistry, and technology. Founded in 2017, KdT has partnered with 70+ science-driven companies across the life science, healthcare, and chemical and materials industries. Prior to becoming a venture capitalist, Malone completed his MD and PhD in computational neuroscience at Georgetown University, where his research focused on machine learning applications in medicine. Before medical school, Malone was a research fellow at the NIH focused on biomarker development for neurodegenerative disease, and completed his BS in neuroscience and behavioral biology at Emory University.

KdT Ventures is an early-stage venture capital firm focused on investing in science-driven companies at the intersection of technology and the physical world. Based in Austin, Texas, and Research Triangle, North Carolina, KdT partners with founders in biotechnology, healthcare, sustainability, and beyond, offering deep technical and strategic support to build transformative companies.   

Manbir Singh is the program manager for BARDA Ventures and the BARDA Accelerator Network at the Biomedical Advanced Research and Development Authority (BARDA), within the US Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR). In his role, Singh helps grow and foster the medical countermeasures startup ecosystem by accelerating the development and commercialization of next-generation health security solutions through entrepreneurial mentorship and non-dilutive funding programs via the BARDA Accelerator Network, along with equity investments through BARDA Ventures. Singh’s background is in infectious disease research before transitioning to venture building, commercialization, and technical and business support for early-stage innovators and entrepreneurs transitioning their technology from the bench to market. Before joining BARDA, Singh led and supported multiple federally funded deep tech startup studios and accelerator programs, managing partnerships, technology sourcing, and due diligence with labs across the DoD, DHS, DOE, NASA, NIST, HHS, the VA, and several universities.

Maryclaire Abowd is a senior business development manager on the Amazon Web Services (AWS) Worldwide Public Sector Global Education team, based in Washington, DC. She works with education and research customers around the world to help them harness the power of cloud technology to advance their missions. With more than 12 years of experience in the IT and services industry, Abowd focuses on go-to-market strategy for the global education sector, with a particular emphasis on academic research, helping universities and research institutions unlock the full potential of cloud and artificial intelligence to drive meaningful outcomes. Her passion for global education was shaped in part by her time at the American University in Cairo Onsi Sawiris School of Business, where she worked prior to joining AWS, an experience that deepened her commitment to expanding access to transformative technology for learners and researchers worldwide. Abowd holds a bachelor of arts degree in international studies and Middle East and Islamic studies from Boston College and a graduate degree from the London School of Economics, and she was awarded a United States Fulbright Award to conduct independent research at Cairo University.

Esther Park, PhD, is the associate director of ventures at Blackbird Laboratories, where she supports early drug discovery research programs and external partnership relationships. Blackbird Laboratories is an independent, nonprofit life sciences incubator dedicated to transforming research breakthroughs into scalable, venture-ready biotech companies. Blackbird collaborates with world-class institutions and scientific partners to propel its portfolio of innovative technologies toward startup formation through its science and business strategy, program management, and capital.

Marine Dumont is a search and evaluation analyst at Servier, based in Boston. In this role, she contributes to the scouting and evaluation of novel therapeutics to support Servier’s oncology pipeline and broader external innovation efforts. She works closely with academic institutions and early-stage biotechnology companies to identify promising scientific opportunities and explore potential collaborations. Prior to joining Servier, Dumont worked at GSK and has built her career within the pharmaceutical industry.

Nitin Goel is Head of Early Commercial for Vaccines & Immune Therapies (V&I) at AstraZeneca. In this role, he leads commercial strategy, planning, and valuation for emerging assets within AZ’s V&I portfolio. He partners with early-stage viral and bacterial product teams to guide development of internal assets – and evaluate external (BD) opportunities – to build a winning portfolio focused on unmet need, competitive positioning, and market access.

Scott T. Shepherd is a Scientific Engagement Manager for East North America at for Johnson & Johnson. He leads strategies to identify, engage, and support pre-spinout and early-stage life science companies aligned with J&J’s innovation priorities. His work focuses on leveraging external programs and strategic partnerships to advance emerging solutions across oncology, immunology, neuroscience, cardiopulmonary disease, and other priority areas.

Bonne Terre Labs was founded on a simple belief: technology should serve humanity, not the other way around. In a world facing unprecedented climate challenges and growing social inequities, we saw an urgent need for tools that translate complex data into actionable insights.
The company partners with communities, public agencies, and researchers to create platforms that make climate and equity data accessible, understandable, and ready to use. From coastal towns preparing for rising seas to cities addressing systemic inequities, Bonne Terre Labs’ work empowers decision-makers with the information they need to build a more resilient and just future.

Cession Oncology is a biotechnology company developing targeted RNA therapeutics for pancreatic cancer. Its lead platform, CO101, is a nanoparticle delivery system designed to overcome key barriers in solid tumors, including poor penetration and off-target toxicity. Developed at Georgetown University and advanced in collaboration with the National Cancer Institute, CO101 enables selective delivery of RNA payloads to tumors and is advancing toward IND.

Hupside is the first company in the world built to fix the AI sameness crisis, the silent force flattening ideas, narrowing innovation, and erasing differentiation across industries. While organizations pour billions into AI tools, 95 percent still fail to see ROI because they aren’t addressing the most important variable: people. Hupside introduced a new category called Original Intelligence (OI), the measurable human capacity to create ideas that break out of AI’s probabilistic patterns. Backed by scientists and experts from Georgetown University and Washington & Lee University, Hupside’s technology quantifies what AI cannot: the human originality that drives real innovation. In a world where AI makes everything faster but increasingly the same, Hupside ensures organizations can still deliver what wins: ideas that are unexpected and unmistakably human.

Nextgen Magnets is a deep-tech startup dedicated to revolutionizing the magnetics industry through the development of rare-earth-free permanent magnets. Utilizing proprietary technology licensed from Georgetown University, the company is addressing the critical supply chain vulnerabilities and environmental costs associated with traditional rare-earth mining.

PushCART Therapeutics is a newly-formed spinout from Georgetown University.  The company has worldwide, exclusive rights to a portfolio of inventions developed by Louis Weiner, who served for 18 years as director of the Lombardi Comprehensive Cancer Center. The company’s technology uniquely addresses a major obstacle in the treatment of solid tumors (e.g., pancreatic, lung, colorectal, comprising 90% of all cancers) – namely, the ability of immune cells to penetrate the dense fibrosis (scar tissue) that walls off the tumor. PushCART’s technology also is applicable to a wide range of fibrotic diseases, which together contribute to about 45 percent of all deaths in Western countries. The company currently expects to be in Ph1 clinical trials by Q2 or Q3 of next year.

Uvantis Therapeutics is a biotechnology company developing live biotherapeutic products targeting the urinary microbiome to prevent and treat recurrent urinary tract infections (rUTIs). Growing evidence shows that disruption of the urinary microbial ecosystem contributes to infection susceptibility and recurrence. The company’s lead program focuses on a defined microbial therapeutic designed to colonize the urinary tract and reduce pathogen overgrowth. By advancing microbiome-driven approaches to urologic disease, Uvantis aims to deliver durable, non-antibiotic treatment options that address a major unmet clinical need while helping reduce antibiotic resistance.

Xlue, an artificial intelligence focused company, is building health foundation models that empower the entire healthcare ecosystem. By adapting frontier, large language models to real-world medical data, Xlue enables smarter decisions, deeper insights, and safer care across clinical practice. Built exclusively on patented technology and proprietary medical data, Xlue bridges frontier AI research and real-world healthcare, creating the foundation layer that connects data, compute, and clinical practice. With deep academic and industrial roots and global clinical partnerships, Xlue is redefining how the healthcare ecosystem leverages trustworthy, explainable, and clinically proven AI to revolutionize medicine. Through their use of Xlue technology, clinical partners are providing a more-informed, hence better, care for their patient population.

1104Health is building the infrastructure for collaborative oncology care. The company’s AI-powered Shared Care Network connects oncologists, clinical trials, and pharmaceutical companies to accelerate patient access to new cancer treatments. While pharmaceutical companies invest billions to develop oncology drugs, most patients are treated in community settings where physicians lack tools to easily identify trials or coordinate care across institutions. As a result, promising therapies often reach patients far too slowly. 1104Health enables oncologists to collaborate, access education, and coordinate patient care through a digital network.

PeraWatt is an advanced materials company redefining energy efficiency in AI data centers, industrial power systems, and electric vehicles by delivering a new class of highly efficient magnetic materials that do not rely on critical minerals or rare earths.

Sophia Spatial AI is pioneering spatial intelligence — AI systems that understand and reason about the physical world. By combining multimodal AI, computer vision, and AR-native interfaces, the company transforms static enterprise knowledge into real-time, context-aware guidance for frontline workers. Its platform bridges digital information and physical environments to improve training, safety, and operational efficiency across industrial sectors.

Capsy is a social photo sharing app where friend groups create shared time capsules for experiences — a spring break trip, a semester, a concert — and unlock them together at the end, seeing all the photos and videos for the first time simultaneously. Because nothing is visible until the reveal, Capsy takes the pressure off in-the-moment sharing, helps people stay present, and makes memories feel worth documenting again instead of getting buried in a camera roll nobody looks at. Launched on the App Store in August 2025, Capsy has secured $20K through Georgetown’s Bark Tank, earned a Forbes feature, and built 85% week-one retention among early users.

Panikcure™ is building an AI-driven Neuro-Decision Intelligence platform to improve decision-making in Central Nervous System (CNS) drug development. Nearly 80% of CNS drugs fail in Phase 2 clinical trials, often due to high placebo response and the lack of objective biomarkers.
By analyzing neural biomarkers such as neuroimaging data, EEG, Panikcure™ aims to distinguish true neural drug effects from placebo noise, enabling earlier and more informed Go/No-Go decisions, reducing costly late-stage failures, while bringing greater precision to neuroscience and supporting the development of more effective neurotherapeutics.

The Petition Company is an AI platform dedicated to protecting democracy by ensuring fair access to the ballot. The platform helps political campaigns, advocacy groups, and grassroots movements verify and manage signatures on their political petition.

REviving REsilience is a Resilience Intelligence company building performance infrastructure for high-burden, high-acuity organizations including healthcare systems, military leadership programs, and executive teams.
The company was founded by a neurosurgeon and an economist who met while studying at Georgetown University’s McDonough School of Business, where their collaboration produced a multi-institutional study on burnout and leadership resilience. Translating insights from functional neurosurgery, behavioral economics, and real-world leadership environments, the team developed a data-driven platform that predicts, measures, and strengthens human performance under sustained pressure.
Through its proprietary RE-DEX™ resilience index, adaptive AI scenario training, and structured leadership programs, REviving REsilience enables organizations to identify hidden burnout risk, improve decision-making under stress, and build resilient teams capable of sustaining peak performance in complex environments